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ABSTRACT: SARS-CoV-2, the mighty manslayer, responsible for COVID-19, has currently killed over 1.54 
million people worldwide and 141,000 in India alone. It has affected around 67 million people globally and 
9.68 million in India. It has quarantined the whole world. Doctors and scientists are working around the clock 
to save the world from this deadly virus. Since the number of patients is increasing rapidly, it is essential to test 
as many suspects as possible. But with the diagnostic tests that are being used currently, the polymerase chain 
reaction, antibody detection (Serological tests), Rapid Diagnostic tests (RDT), antigen tests and Isothermal 
Amplification assays are time consuming and there is a high chance that the test might come back with the 
wrong results. SHERLOCK and DETECTR are CRISPR-based diagnostic tool that were recently worked upon 
and showed very promising results. The test results come back in less than 40 minutes and the tests are far more 
accurate than all of the current diagnostics which makes them far more efficient than the others. 
Keywords: COVID-19; CRISPR; DETECTR; SARS-CoV-2; SHERLOCK. 
1. INTRODUCTION 
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been affecting the world 
since December 2019. It was first identified in Wuhan, China and since then, it has been on a continuous force 
of invasion to humanity. It is known to cause the “Coronavirus Disease 2019” or COVID-19. SARS-CoV-2 
has been known to cause many complications including pneumonia, viral sepsis, acute respiratory distress 
syndrome, kidney failure, cytokine release syndrome etc. that are accountable for various symptoms or 
pathological changes like spike in fever, dry cough and fatigue being the most common ones. Since the 
outbreak, the whole world has been working to find a cure for COVID-19. Many of the research institutes 
have also been working on various possible diagnostic tools so as to speed up the detection of SARS-CoV-2 
[1, 2]. One such attempt to redefine the process of diagnosis and eliminate the time constraint was to use 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) which is a universally acclaimed 
genome-editing tool when paired up with the “CRISPR Associated Protein 9” (Cas9). “Distant cousins” of 
Cas9, Cas12a and Cas13 have now been worked upon and found to be two of the most efficient tools of 
diagnosis. DETECTR (DNA Endonuclease Targeted CRISPR Trans Reporter), a CRISPR Cas12-based 
diagnostic tool (discovered by researchers of Mammoth Biosciences) and SHERLOCK (Specific High-
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sensitivity Enzyme Reporter unlocking), a CRISPR Cas13-based diagnostic tool (discovered by McGovern 
Institute) are the two recently found diagnostic tools based on CRISPR which is time efficient and 
scientifically more accurate. SHERLOCK refers to the method using a CRISPR enzyme for collateral 
detection with any pre-amplification of RNA whereas DETECTR refers to the specific instance of using 
Cas12a collateral detection after pre-amplification by RPA (Recombinase Polymerase Amplification). The 
article firmly projects on how these two CRISPR-based tools function and achieve more credibility than the 
currently used diagnostics kits [3]. 
2. COVID-19 AND ITS PATHOPHYSIOLOGY 
Coronavirus disease-19 (COVID-19) is a potentially fatal disease caused by the SARS-CoV-2. An 
initial outbreak turned epidemic further turned pandemic ultimately lead to mass isolation or rather a 
quarantine, due to the person-to-person transmission of the infection. Some of the most common 
symptoms include fever, cough and lethargy on the onset of the COVID-19 illness. With a median of 14 days, 
there are about 6-41 days period between the onset of the virus and death of the infected. The symptoms 
further elevate to lymphopenia, haemoptysis, fibrosis, dyspnoea, diarrhoea added on to which is the 
increase in sputum production [1, 2]. One huge difference between SARS and MERS vs. SARS-COV- 2 
is that the latter developed gastro-intestinal symptoms such as diarrhoea while the former had highly rare 
cases with gastro-intestinal symptoms. The virus has spikes that are made up of proteins called the S-
proteins. This protein is a key that attaches the virus to a human [4, 5]. The human alveoli have 3 types 
of cells: Type 1 cells that are squamous epithelial cells for gas exchange, Type 2 cells that are surfactants 
to absorb the water molecules so that the alveoli doesn’t collapse and Type 3 Macrophages to kill 
pathogens if entered. The Type 2 cells i.e., the surfactants have a protein receptor called ACE2 
(angiotensin converting enzyme-2; helps to maintain blood pressure). This ACE2 acts as a receptor 
where the S-protein binds and thus the virus enters the Type-2 cells.Once the virus enters the cells, it 
replicates and makes multiple copies of itself. Initially only the viral RNA enters the cell and hijacks its 
machinery. The ribosomes present in the cell, translate the viral RNA and produce 2 proteins. Further it 
translates the RNA this time in 3’-5’ direction and synthesizes all the components of the virus such as the 
envelope, spike and assembles all the components into viruses and cell lysis takes place [5, 6]. Since the ACE 
2 was responsible for the blood pressure maintenance, after the lysis there is a sudden drop in blood 
pressure and the blood vessels are dilated [7]. With millions of viruses in the alveoli, it causes irritation 
which further develops into a cough wherein a bunch of these viruses are coughed out which can be 
transmitted to other people. The alveoli that contains all the viruses prepares itself to burst and when it 
does so, it releases pro-inflammatory chemicals causing redness, swelling, pain, etc. apart from this, 
these chemicals make the blood vessels porous and permeable enabling the plasma and WBC’s to flow 
between the vessel and alveoli and also into the alveoli trashing the gaseous exchange system leading to 
what is called “Acute Respiratory Distress Syndrome”. This is localized inflammation. When these 
chemicals enter the bloodstream and affect the whole body, it elevates to what is called a systemic 
inflammation resulting in septic syndromes followed by organ failures ultimately resulting in death [6, 7]. 
Figure 1 depicts the process of infection by SARS-CoV-2. 
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Figure 1. SARS-CoV-2 and its pathophysiology. 
3. GENOME ANALYSIS OF SARS-COV-2 
All corona viruses have a genome size ranging from 26,000 to 32,000 including a variable number of 
open reading frames or ORF’s (usually 6 to 11 in number). The first ORF represents 67% of the viral genome 
that encodes for non- structural proteins whereas the remaining ORF’s code for accessory proteins and 
majorly structural proteins including the spike surface glycoprotein (encoded by the S-gene), small envelope 
protein (encoded by E-gene), matrix protein (encoded by M-gene) and nucleocapsid protein (encoded by N-
gene). On further analysis and comparison with SARS-CoV and MERS-CoV, it was identified that they are 
almost identical with only five nucleotide difference in the genome of approximately 2.9 kb nucleotides [2, 8]. 
SARS-CoV-2 was inferred to have 14 ORFs encoding 27 proteins. Also, an examination of amino acid 
substitution in SARS-CoV-2 (when compared to SARS-CoV) showed that there was a substitution of a total 
of 380 amino acids. Most of these amino acid substitutions were found in the structural proteins. This 
indirectly implies that the little mutations that distinguish SARS-CoV-2 from SARS-CoV are in the genes E, 
N, M and S. There were no substitutions of amino acids in the non- structural proteins [9-11]. 
4. CURRENT MEDICAL APPROACH 
The treatment is based on oral drug intakes. Anti-viral hydroxychloroquine with regular doses of 
azithromycin are prescribed as the first line medication. Hydroxychloroquine is known to change the pH of 
endosomes thereby preventing the entry of the virus. It inhibits the infection of cells by SARS-CoV-2. 
Azithromycin belongs to class of macrolide antibiotics which prevents the currently suffering patient from 
getting any other bacterial infection. Other complimentary doses include vitamins C, B-complex and zinc 
supplements which are carried out till the patient is out of threat. These supplements act as immunity boosters. 
Doses of Oseltamivir and Remedesivir are then followed as the second line of medication. These drugs are 
known to inhibit viral RNA synthesis thereby inhibiting viral replication [12-14]. 
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5. PREVAILING METHODS OF DIAGNOSIS  
5.1. Cobas® SARS-CoV-2 test  
It is software which specifically detects SARS-CoV-2 with a full process negative control and positive 
control. It is a qualitative assay done with Cobas® 6800/8800 systems. The major drawback of this tool is that 
it is very expensive and cannot be transported very frequently due to its heavy machinery [14]. 
5.2. Real-time-PCR assay 
It is a standard test for COVID-19 and other viruses worldwide which require huge equipments and a 
lot of time for the detection of the virus. Moreover its sensitivity has dropped down to as low as 66-88% thus 
requiring tools that are more sensitive and efficient [15, 16]. 
5.3. Abbott real-time SARS-CoV-2 assay 
Addressing the urgent needs of the people this assay provides fully automated solution catering about 
the detection of around 470 patients in 24 hours [17]. 
5.4. Perkin Elmer SARS-CoV-2 real-time RT-PCR assay 
A reliable and high quality tool used for invitro diagnosis of COVID-19. This test can be used to 
detect SARS-CoV-2 RF1ab and N genes in 400 µL of the sputum samples from nasopharyngeal and 
oropharyngneal regions. 
5.5. Other methods of diagnosis include 
5.5.1. Isothermal nucleic acid amplification test 
Processes like -loop mediated isothermal amplification along with reverse transcription RT-LAMP 
combined with pH indicator allows direct detection of viral RNA by a change in colour. 
5.5.2. Antibody test 
Otherwise known as a serology test, tested for the presence of IgM and IgG which show up in the 
blood on the onset of the virus and 7–10 days after the entry of the virus respectively. 
5.5.3. Radiological test 
Since the studies that can be made from a CT scan such as a consolidation or a ground-glass opacity is 
not a unique symptom of COVID-19 alone, the result cannot be clinically accepted and also the sensitivity is a 
variable an in case of radiological tests [18, 19]. 
The various methods of diagnosis that are acceptable by the WHO are presented in Table 1. 
 
Table 1. Various methods of diagnosis accepted by WHO for detection of SARS-CoV-2 with its manufacturer and date 
of acceptance. 
Date listed Product description Manufacturer 
April 3, 2020 Cobas SARS-CoV-2, a software-based detection Roche Molecular Systems 
April 7, 2020 RT-PCR assay (real time-Polymerase Chain Reaction) Primerdesign 
April 9, 2020 Abbot Real-time SARS-CoV-2 (a large scale diagnostic platform) Abbot Molecular 
April 24, 2020 Perkin Elmer Real-time RT-PCR assay (more reliable in vitro- assay) SYM- BIO LiveScience 
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6. INTRODUCTION TO CRISPR 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome editing tool that 
was first observed in Escherichia coli in 1987 and was found to be functioning as an immune system in 
bacteria and archaea [20]. Various genomic analyses around 2000’s gave a clear picture of CRISPR. CRISPR 
and Cas proteins together worked as an acquired- immunity system for the prokaryotic cells and protected it 
against viruses and various plasmids. CRISPR in prokaryotes is similar to the property of memory in human 
immune system. On the first invasion by a virus or plasmid, the cell keeps a part of the attacker’s genome, just 
like a mug shot, so that it can protect itself from further attack [21]. The CRISPR-Cas protein system is 
analogous to the RNAi (RNA interference system). One of the major characteristics of the CRISPR system is 
that the repeat sequences with a constant length generally have dyad symmetry and hence form a palindromic 
structure. Its ability to identify specific genome sequences and edit it when in association with Cas protein 
makes it a very desirable tool in the field of genetic engineering and has taken the scope of genome editing to 
the very next level [22, 23]. Due to this very reason CRISPR-Cas9 system has been used for various research 
programs. For example, in December 2013, the genetic mutation of the Crygc gene in mice was corrected 
using CRISPR-Cas9 system [24]. Figure 2, illustrates the activity of CRISPR-Cas9 system which makes it a 
viable genome editing tool. 
All this accounts for the variety of fields where CRISPR systems can be viably used. Further studies 
and research brought to notice the presence of Cas12a and Cas13 proteins that are very different from Cas9 
but when paired up with CRISPR, it can be used in a variety of ways for detection, confirmation and analyses 
of the desired genes (or DNA sequences). DETECTR is the diagnostic tool based on CRISPR-Cas12a system 
whereas SHERLOCK is the diagnostic tool based on CRISPR-Cas13 system. The above mentioned tools are 
further discussed in detail [25, 26]. 
 
Figure 2. Cas9 complex. 
6.1. General mechanism of CRISPR systems 
Engineered CRISPR systems consist of two major components: the guide RNA (gRNA) and a CRISPR 
associated endonuclease (Cas protein). The gRNA consists of two specific regions: scaffolding that is 
essential for the attachment of the Cas protein and the spacer consisting of approximately 20 nucleotides that 
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is complimentary to the genomic target. There are two conditions that are to be fulfilled by the genomic 
target: (1) the target should be a set of 20 nucleotides that are specific and unique compared to the rest of the 
genome, (2) the target should be present immediately adjacent to the PAM (protospacer adjacent motif) 
sequence. The PAM sequence serves as a binding signal for Cas protein [27, 28]. 
The scaffolding interacts with the Cas protein to form a ribonucleoprotein. Once the PAM sequence is 
recognised, the Cas protein attaches itself to the PAM and the spacer is ready to bind to the target. If the spacer 
sequence shares sufficient homology with the target genome, the Cas protein starts functioning. In case of Cas9 
it starts annealing the genome whereas in case of Cas12a and Cas13, the genome is shredded off [27-29]. 
The CRISPR systems of SHERLOCK and DETECTR are quite similar. The mechanism includes 
construction of a guide ssRNA that identifies a specific gene set that is unique to the virus in diagnosis. When 
the guide ssRNA binds to the set of genes, both Cas12 and Cas13 start cutting all the available nucleic acids in 
the system. Therefore when additional reporter RNA molecules tagged with a fluorescent dye (fluorescein 
amidite, FAM) are present within the system and Proteins start cutting the nucleic acids, even reporters are 
cut. When these RNA molecules are cut, they produce light indicating that the protein is activated and thereby 
concluding that the sample has the genes that are being looked for [25, 27]. 
6.2. CRISPR as a diagnostic tool 
CRISPR is nothing but an adapted immune system of the bacteria against the viruses. The Cas proteins 
are CRISPR associated endonucleases otherwise known as the molecular scissors. There are 3 Cas proteins 
that are involved in the applications with CRISPR namely: Cas9, Cas12 and Cas13 [25]. Cas9 usually does 
the precise cuttings in genome editing while Cas12 and Cas13 help in the detection of genomes and also 
provides signals as a sign of detection making them a better diagnostic tool. This sign is produced by a 
process called Trans-cleavage. Cas12 and Cas13 use a guide RNA and look out for complimentary sequences 
of nucleic acids in the host genome. Cas12 cuts DNA while Cas13 on the other hand cuts RNA which binds to 
the guide RNA when it finds its complementary sequence. This cutting is known as the Cis-cleavage. While 
doing this the Cas proteins also switch on their Trans-cleavage which is non-specific cleavage of any nucleic 
acid sequence they come across. If an artificial nucleic acid sequence, often referred to as a reporter that is 
fluorescence quenched (FQ) with FAM (Fluorescein amidite), is added along with the Cas proteins, the non-
specific cleavage of these sequences will provide a visible signal with which we can detect the presence of the 
viral genome as they are tagged with fluorescent dyes [23, 30, 31]. Figure 3 depicts the general workflow of 
CRISPR-based diagnostic tools. 
 
Figure 3. General workflow of CRISPR-based diagnostic tools. 
6.3. DETECTR- CRISPR-CAS12A based diagnostic tool 
DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR) is an assay that is designed to 
perform simultaneous reverse transcription and isothermal amplification using loop mediated amplification (RT- 
LAMP) for the RNA that is extracted from the nasopharyngeal or oropharyngeal swabs in a universal transport 
medium (UTM) [32, 33]. Since every CRISPR-Cas based system has a guide RNA, for this process, a guide 
RNA is designed which specifically compliments either of the four genes that code for the structural proteins like 
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the S-gene (spike protein), N-gene (nucleoprotein ), E-gene (envelope protein) and the M-gene (matrix protein). 
But the designed primers targeted the N2 region N-gene and E-gene because they had the perfect PAM 
sequences which the other genes lacked. Once the desired gRNA is constructed, it is inserted in the sample with 
the Cas12a protein. The scaffolding of the gRNA binds with the Cas12a to form a ribonulceoprotein complex. 
Cas12a then finds PAM and attaches itself. The spacer then recognises the target sequence and attaches itself. 
When this is sensed by the Cas12a, it activates itself and starts working as a paper-shredder. Cas12 will start 
cutting all the available nucleic acids without stopping. Therefore there are RNA reporter molecules tagged with 
a fluorescent dye (fluorescein amidite, FAM) that produces a colour when cut. Indirect assessment is done by the 
cleavage of these reporter molecules and their colour emission. The sample is then added onto a flow detection 
system using a lateral flow strip. If SARS-CoV-2 is absent, the reporter remains intact and collects at the first 
detection line, the control capture line on the flow strip. If the sample is positive, the Cas-gRNA complex will cut 
the target and the reporter molecules. These cleaved fragments collect at a separate location, the target capture 
line on the flow strip. Gold nanoparticles are also used which bind to the FAM molecule on the reporter, thus 
generating a visual readout on the strip. This is how the test makes diagnosis simple and accurate [32, 34]. 
This diagnostic test is rapid (takes under 40 minutes), easy to implement and accurate. The researchers at 
Mammoth Biosciences have tested this tool with 36 patients affected by COVID-19 infection and 42 patients 
with other viral respiratory infections. This assay is faster than all the currently prescribed diagnostic tests and is 
also a visual alternative, making it more efficient [32, 33, 35]. Figure 4 depicts the activity of Cas12a essential 
for the functioning of DETECTR. 
 
Figure 4. The activity of Cas12a. 
6.4. SHERLOCK- CRISPR-CAS13 based diagnostic tool 
Specific High-Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK), is an in vitro nucleic acid–
detection platform with attomolar sensitivity, based on nucleic acid amplification and Cas13a-mediated 
collateral cleavage of a reporter RNA [33, 36]. Nasopharyngeal or oropharyngeal swab sample of the person 
is collected. This sample is purified with all lysis reactions with proteases, lipases, etc., such that only the 
nucleic acid remains. The SARS-CoV-2 E-gene (envelope), N-gene (nucleoprotein) and the DNA specimen 
collected from the samples are amplified using any amplification technique such as RPA (recombinase 
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polymerase amplification) (37-42°C) or LAMP (loop mediated isothermal amplification) (62°C). To this the 
Master mix is added (37°C) which consists of Cas-13-crRNA, FAM-FQ reporter and T-7 transcriptase 
enzyme. When the Cas13 detects the presence of either the N-gene or E-gene of the SARS CoV-2, it starts to 
cut off every molecule that it happens to pass including the receptors. This “collateral diagnosis” provides a 
signal which helps to detect the presence of the viral genes through a lateral flow strip. Test kits based on 
CRISPR is a DNA/RNA equivalent of a pregnancy test with same principle lying behind it. The total assay 
reaction time is around 30-40 minutes and the net assay and result time is maximum 45 minutes [37-39]. 
Figure 5 depicts the activity of Cas13 essential for the functioning of SHERLOCK. 
 
 
Figure 5. The activity of Cas13. 
7. COMPARISON OF RT-PCR AND CRISPR-BASED MOLECULAR DIAGNOSTICS 
Currently the most preferred diagnostic tool used for detection is RT-PCR. This is mostly due to the fact that 
the process of PCR has been used since many years for diagnosis and therefore the handling is very well known by 
microbiologists and pathologists. Following is the table of comparison between the most used RT-PCR and CRISPR-
based diagnostic tools [3]. Figures 6 and 7 illustrate the RT- PCR method and CRISPR-diagnostic tools respectively. 
Table 2 shows the difference between the RT-PCR and CRISPR based detection methods. 
 
Table 2. The difference between the presently used RT-PCR method of detection and CRISPR based detection on various basis [3]. 
Methods RT-PCR CRISPR-Based Diagnostic Tools 
Specificity Highly specific in action Highly specific in action 
Time consumed for 
the results 
The tests results can take up to 5-6 hours to 
arrive. 
Within 45 minutes. 
DETECTR takes less than 40 minutes. 
SHERLOCK takes up to 45 minutes. 
Bulk of 
instrumentation 
It requires many different instruments including 
thermal cycler and fluorimeter 
No bulk instrumentation is required for 
either of the tools. 
Cost efficiency 
Due to requirement of bulky instrumentation, 
Cost of carrying out the procedure is very high. 
Both the diagnostics are very cost efficient. 
Disadvantage 
Chances of false negative results are 
considerable, due to improper handling. 
Off-targets may exist. 
Target 
Different labs have different targets like N-
gene, Orflab etc. 
SHERLOCK: N-gene and S-gene 
DETECTR: E-gene and N-gene 
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Figure 6. Real time RT-PCR assay. 
 
7.1. LIMITATIONS 
CRISPR-Cas Systems as diagnostic tools is relatively a recent concept. The F.D.A. approved the 
emergency use of SHERLOCK to detect the presence of SARS-CoV-2 in the U.S.A. [40]. There have also 
been viable clinical validations for the compatibility and accuracy of DETECTR [41]. But the biggest 
problem lies in the fact that these CRISPR-Cas diagnostic tools are not accessible to a lot of countries. 
Moreover, even if developing countries might get their hands on this technology and since it is a new process, 
proper training has to be arranged so that lab technicians get accustomed to the process. Based on technicality, 
there is a chance that off-targets may exist [3]. Another limitation of CRISPR-based diagnostic tools is that, 
the reaction mixtures need to be prepared which involves protein purification. Expertise in this methodology 
is required to properly extract and purify the desirable proteins [36, 42]. 
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Figure 7. CRISPR-based diagnostic tools. 
8. CONCLUSION 
SHERLOCK and DETECTR, the two CRISPR-based diagnostics, are revolutionary in the idea of 
efficiency, analyses and accuracy in the field of diagnosis. These tools are very easy to handle and can be 
operated on a large scale basis with ease. There are no additional requirements for the whole process. The 
above methodology of both the processes makes it very clear that the procedures are highly specific and 
sensitive. Both of the two molecular diagnostic technologies, SHERLOCK and DETECTR, can be used to 
detect specific RNA and DNA at attomolar level (a concentration of 10-18 moles per litre). Two of the biggest 
advantages are that they can detect an early infection and are very time efficient. DETECTR gives out the test 
results in less than 40 minutes and SHERLOCK can give results in 45 minutes. All this makes both 
SHERLOCK and DETECTR very viable as a diagnostic tool, not just for the detection of SARS-CoV-2 but 
any viral infection in the human physiology. 
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